Key result
Treatment with the Supraflex stent in patients with coronary artery disease resulted in low one-year complication rates, including 1% for target lesion revascularization, myocardial infarction, stent thrombosis, and cardiac death.
Why the study?
What are the clinical outcomes and complication rates associated with the Supraflex sirolimus-eluting stent at one year in patients with coronary artery disease?
Cross-Sectional (n=287)
No
What are the clinical outcomes and complication rates associated with the Supraflex sirolimus-eluting stent at one year in patients with coronary artery disease?
The use of the Supraflex sirolimus-eluting stent with a biodegradable polymer in patients with coronary artery disease is associated with low rates of target lesion revascularization, myocardial infarction, stent thrombosis, and cardiac death at one year.
Peak TLR at 6 months warrants close surveillance then; extends temporal restenosis data for sirolimus-eluting stents.
Cardiovascular disease is one of the most important causes of morbidity and mortality in the world. Treatment in most patients is percutanseous coronary intervention. One of new generation drug-eluting stent (DES) is Sirolimus Eluting Stent. The current study was aimed to investigate the clinical outcomes and complications of treatment with supraflex stent during one year follow up in patients with coronary artery disease. This cross-sectional study was performed on patients with myocardial ischemia who were candidate for coronary angioplasty between 2017-2018 in Imam Reza Hospital, Mashhad, Iran.. Patients were followed for four primary end points including Target lesion revascularization (TLR), stent thrombosis (ST), myocardial infarction (MI) and cardiac death (CD) for one year. Descriptive data were analyzed by Freidman at a significance level of 0.05. A total of 287 patients were enrolled in the study. There was no TLR, MI, ST and CD records in the one month follow up. Six months follow up demonstrated three TLR patients and three MI patients, but no ST and death were reported. After one year follow up, three cases of CD and four ST cases were found in patients treated with supraflex stent. Based on the Freidman test, the highest rate of TLR was revealed in a six-month follow-up when comparing with one-month and twelve-month follow-up (p = 0.05). No significant relationship was found between the other cases. The most common complications associated with supraflex stent were TLR and MI in six-month follow-up. The most likely occurrence of CD and ST were found in one year follow up.
No takes yet. Share an insight, caveat, or question.
Sharifi et al. (2019) conducted a cross-sectional in Coronary artery disease (n=287). Supraflex stent was evaluated on Target lesion revascularization (TLR) at 1 year. Treatment with the Supraflex stent in patients with coronary artery disease resulted in low one-year complication rates, including 1% for target lesion revascularization, myocardial infarction, stent thrombosis, and cardiac death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: